Drug intelligence / Profile preview

ICS-001

Development stage: Unknown
Lead developer: bioX
Modality: Cell Therapies
Administration: Intramuscular

Overview

ICS-001 is an injectable cell scaffold (ICS) designed to enhance cell-based angiogenic therapy for chronic limb-threatening ischemia (CLTI). It consists of bioabsorbable polymer microspheres coated with hydroxyapatite nanocrystals. Designed for intramuscular injection, ICS-001 is used in combination with autologous peripheral blood mononuclear cells (PBMNCs), specifically CD34-rich cells mobilized by G-CSF and CXCR4 inhibitors. The scaffold functions by providing a supportive physical microenvironment that improves the local retention and therapeutic function of transplanted cells, thereby promoting angiogenesis. It is currently being evaluated in investigator-initiated exploratory clinical trials and is developed within a medical device regulatory framework.

Other names: Injectable Cell Scaffold

Beyond the preview

Go deeper on ICS-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ICS-001.

Explore the full profile